A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia

Trial Profile

A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Cariprazine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2016 Status changed from recruiting to completed.
    • 25 Aug 2015 According to an Allergan media release, pooled data from phase II/III studies will be presented at the 28th European College of Neuropsychopharmacology (ECNP) annual congress.
    • 26 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top